Rani Therapeutics Holdings, Inc (RANI) Files up to $100M IPO

Rani Therapeutics Holdings, Inc (NASDAQ: RANI) files for an up to $100,000,000 IPO.

The company describes itself as: "We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage."

BofA Securities, Stifel, Cantor and Canaccord Genuity will serve as underwriters.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Seagate board member Arumugavelu to step down at annual meeting
• Stifel on Eos Energy Enterprises (EOSE) amid 10% gain: 'we view the collaboration with Google as a positive step for EOSE'